- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 542363, 8 pages
The Role of Calprotectin in Pediatric Disease
1Department of Pediatric Surgery, Alexandroupolis University Hospital, Democritus University of Thrace School of Medicine, Dragana, 68100 Alexandroupolis, Greece
2Second Department of Propedeutic Surgery, “Laiko” General Hospital, National and Kapodistrian University of Athens, Medical School, 17 Agiou Thoma Street, 11527 Athens, Greece
3Third Department of General Surgery, “Attiko” General Hospital, National and Kapodistrian University of Athens, Medical School, 1 Rimini Street, 1246 Athens, Greece
4Department of Pediatrics, Alexandroupolis University Hospital, Democritus University of Thrace School of Medicine, Dragana, 68100 Alexandroupolis, Greece
Received 29 April 2013; Revised 6 August 2013; Accepted 26 August 2013
Academic Editor: Gianluca Terrin
Copyright © 2013 George Vaos et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- S. Yui, Y. Nakatani, and M. Mikami, “Calprotectin (S100A8/S100A9), an inflammatory protein complex from neutrophils with a broad apoptosis-inducing activity,” Biological and Pharmaceutical Bulletin, vol. 26, no. 6, pp. 753–760, 2003.
- I. Stříž and I. Trebichavský, “Calprotectin—a pleiotropic molecule in acute and chronic inflammation,” Physiological Research, vol. 53, no. 3, pp. 245–253, 2004.
- D. F. Stroncek, R. A. Shankar, and K. M. Skubitz, “The subcellular distribution of myeloid-related protein 8 (MRP8) and MRP14 in human neutrophils,” Journal of Translational Medicine, vol. 3, article 36, 2005.
- L. Rodrigo, “Fecal calprotectin,” Revista Espanola de Enfermedades Digestivas, vol. 99, no. 12, pp. 683–688, 2007.
- N. S. McNutt, “The S100 family of multipurpose calcium-binding proteins,” Journal of Cutaneous Pathology, vol. 25, no. 10, pp. 521–529, 1998.
- J. A. Tibble and I. Bjarnason, “Non-invasive investigation of inflammatory bowel disease,” World Journal of Gastroenterology, vol. 7, no. 4, pp. 460–465, 2001.
- R. J. Passey, K. Xu, D. A. Hume, and C. L. Geczy, “S100A8: emerging functions and regulation,” Journal of Leukocyte Biology, vol. 66, no. 4, pp. 549–556, 1999.
- D. Viemann, K. Barczyk, T. Vogl et al., “MRP8/MRP14 impairs endothelial integrity and induces a caspase-dependent and -independent cell death program,” Blood, vol. 109, no. 6, pp. 2453–2460, 2007.
- A. Ahmad, D. L. Bayley, S. He, and R. A. Stockley, “Myeloid related protein-8/14 stimulates interleukin-8 production in airway epithelial cells,” American Journal of Respiratory Cell and Molecular Biology, vol. 29, no. 4, pp. 523–530, 2003.
- D. Viemann, A. Strey, A. Janning et al., “Myeloid-related proteins 8 and 14 induce a specific inflammatory response in human microvascular endothelial cells,” Blood, vol. 105, no. 7, pp. 2955–2962, 2005.
- K. Sunahori, M. Yamamura, J. Yamana et al., “The S100A8/A9 heterodimer amplifies proinflammatory cytokine production by macrophages via activation of nuclear factor kappa B and p38 mitogen-activated protein kinase in rheumatoid arthritis,” Arthritis Research and Therapy, vol. 8, no. 3, article no. R69, 2006.
- W. Nacken, J. Roth, C. Sorg, and C. Kerkhoff, “S100A9/S100A8: myeloid representatives of the S100 protein family as prominent players in innate immunity,” Microscopy Research and Technique, vol. 60, no. 6, pp. 569–580, 2003.
- S. K. Bunn, W. M. Bisset, M. J. C. Main, and B. E. Golden, “Fecal calprotectin as a measure of disease activity in childhood inflammatory bowel disease,” Journal of Pediatric Gastroenterology and Nutrition, vol. 32, no. 2, pp. 171–177, 2001.
- S. Ashorn, T. Honkanen, K.-L. Kolho et al., “Fecal calprotectin levels and serological responses to microbial antigens among children and adolescents with inflammatory bowel disease,” Inflammatory Bowel Diseases, vol. 15, no. 2, pp. 199–205, 2009.
- K.-L. Kolho, D. Turner, G. Veereman-Wauters et al., “Rapid test for fecal calprotectin levels in children with Crohn's disease,” Journal of Pediatric Gastroenterology and Nutrition, vol. 55, no. 4, pp. 436–439, 2012.
- I. D. Kostakis, K. G. Cholidou, A. G. Vaiopoulos, I. S. Vlachos, D. Perrea, and G. Vaos, “Fecal calprotectin in pediatric Inflammatory bowel disease: a systematic review,” Digestive Diseases and Sciences, vol. 58, no. 2, pp. 309–319, 2013.
- M. Komraus, H. Wos, S. Wiecek, M. Kajor, and U. Grzybowska-Chlebowczyck, “Usefulness of feacal calprotectin measurement in children with various types of inflammatory bowel disease,” Mediators of Inflammation, vol. 2012, Article ID 608249, 5 pages, 2012.
- S. T. Leach, Z. Yang, I. Messina et al., “Serum and mucosal S100 proteins, calprotectin (S100A8/S100A9) and S100A12, are elevated at diagnosis in children with inflammatory bowel disease,” Scandinavian Journal of Gastroenterology, vol. 42, no. 11, pp. 1321–1331, 2007.
- U. L. Fagerberg, L. Lööf, U. Myrdal, L.-O. Hansson, and Y. Finkel, “Colorectal inflammation is well predicted by fecal calprotectin in children with gastrointestinal symptoms,” Journal of Pediatric Gastroenterology and Nutrition, vol. 40, no. 4, pp. 450–455, 2005.
- A. Bremner, S. Roked, R. Robinson, I. Phillips, and M. Beattie, “Faecal calprotectin in children with chronic gastrointestinal symptoms,” Acta Paediatrica, vol. 94, no. 12, pp. 1855–1858, 2005.
- M. Joishy, I. Davies, M. Ahmed et al., “Fecal calprotectin and lactoferrin as noninvasive markers of pediatric inflammatory bowel disease,” Journal of Pediatric Gastroenterology and Nutrition, vol. 48, no. 1, pp. 48–54, 2009.
- M. A. Quail, R. K. Russell, J. E. van Limbergen et al., “Fecal calprotectin complements routine laboratory investigations in diagnosing childhood inflammatory bowel disease,” Inflammatory Bowel Diseases, vol. 15, no. 5, pp. 756–759, 2009.
- A. Diamanti, F. Colistro, M. S. Basso et al., “Clinical role of calprotectin assay in determining histological relapses in children affected by inflammatory bowel diseases,” Inflammatory Bowel Diseases, vol. 14, no. 9, pp. 1229–1235, 2008.
- R. Berni Canani, G. Terrin, L. Rapacciuolo et al., “Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease,” Digestive and Liver Disease, vol. 40, no. 7, pp. 547–553, 2008.
- D. Walkiewicz, S. L. Werlin, D. Fish, M. Scanlon, P. Hanaway, and S. Kugathasan, “Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease,” Inflammatory Bowel Diseases, vol. 14, no. 5, pp. 669–673, 2008.
- S. K. Bunn, W. M. Bisset, M. J. C. Main, E. S. Gray, S. Olson, and B. E. Golden, “Fecal calprotectin: validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease,” Journal of Pediatric Gastroenterology and Nutrition, vol. 33, no. 1, pp. 14–22, 2001.
- P. F. van Rheenen, “Role of fecal calprotectin testing to predict relapse in teenagers with inflammatory bowel disease who report full disease control,” Inflammatory Bowel Diseases, vol. 18, no. 11, pp. 2018–2025, 2012.
- U. L. Fagerberg, L. Lööf, J. Lindholm, L.-O. Hansson, and Y. Finkel, “Fecal calprotectin: a quantitative marker of colonic inflammation in children with inflammatory bowel disease,” Journal of Pediatric Gastroenterology and Nutrition, vol. 45, no. 4, pp. 414–420, 2007.
- R. B. Canani, L. T. de Horatio, G. Terrin et al., “Combined use of noninvasive tests is useful in the initial diagnostic approach to a child with suspected inflammatory bowel disease,” Journal of Pediatric Gastroenterology and Nutrition, vol. 42, no. 1, pp. 9–15, 2006.
- P. Henderson, A. Casey, S. J. Lawrence et al., “The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease,” American Journal of Gastroenterology, 2012.
- M. R. Konikoff and L. A. Denson, “Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease,” Inflammatory Bowel Diseases, vol. 12, no. 6, pp. 524–534, 2006.
- P. F. van Rheenen, E. van de Vijver, and V. Fidler, “Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis,” British Medical Journal, vol. 341, article c3369, 2010.
- E. van de Vijver, A. B. Schrender, W. R. Cnossen, et al., “Safety ruling out inflammatory bowel disease in children and teenagers without referral for endoscopy,” Archives of Disease in Childhood, vol. 97, no. 12, pp. 1014–1018, 2012.
- R. B. Canani, L. Rapacciuolo, M. T. Romano et al., “Diagnostic value of faecal calprotectin in paediatric gastroenterology clinical practice,” Digestive and Liver Disease, vol. 36, no. 7, pp. 467–470, 2004.
- R. J. Shulman, M. N. Eakin, D. I. Czyzewski, M. Jarrett, and C.-N. Ou, “Increased gastrointestinal permeability and gut inflammation in children with functional abdominal pain and irritable bowel syndrome,” Journal of Pediatrics, vol. 153, no. 5, pp. 646–650, 2008.
- K.-L. Kolho, T. Raivio, H. Lindahl, and E. Savilahti, “Fecal calprotectin remains high during glucocorticoid therapy in children with inflammatory bowel disease,” Scandinavian Journal of Gastroenterology, vol. 41, no. 6, pp. 720–725, 2006.
- V. M. Navas López, J. Blasco Alonso, C. Sierra Salinas, A. Barco Gálvez, and M. I. Vicioso Recio, “Efficacy of exclusive enteral feeding as primary therapy for paediatric Crohn's disease,” Anales de Pediatria, vol. 69, no. 6, pp. 506–514, 2008.
- M. E. Baldassarre, N. Laforgia, M. Fanelli, A. Laneve, R. Grosso, and C. Lifschitz, “Lactobacillus GG improves recovery in infants with blood in the stools and presumptive allergic colitis compared with extensively hydrolyzed formula alone,” Journal of Pediatrics, vol. 156, no. 3, pp. 397–401, 2010.
- A. Hämäläinen, T. Sipponen, and K.-L. Kolho, “Infliximab in pediatric inflammatory bowel disease rapidly decreases fecal calprotectin levels,” World Journal of Gastroenterology, vol. 17, no. 47, pp. 5166–5171, 2011.
- N. Kapel, C. Roman, D. Caldari et al., “Fecal tumor necrosis factor-α and calprotectin as differential diagnostic markers for severe diarrhea of small infants,” Journal of Pediatric Gastroenterology and Nutrition, vol. 41, no. 4, pp. 396–400, 2005.
- C. C. Chen, J. L. Huang, C. J. Chang, and M. S. Kong, “Fecal calprotectin as a correlative marker in clinical severity of infectious diarrhea and usefulness in evaluating bacterial or viral pathogens in children,” , Journal of Pediatric Gastroenterology and Nutrition, vol. 55, no. 5, pp. 541–547, 2012.
- A. Carroccio, G. Iacono, M. Cottone et al., “Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children,” Clinical Chemistry, vol. 49, no. 6, part 1, pp. 861–867, 2003.
- M. L. Stoll, A. S. Patel, and M. Punaro, “Fecal calprotectin in children with the enthesitis-related arthritis subtype of juvenile idiopathic arthritis,” Journal of Rheumatology, vol. 38, no. 10, pp. 2274–2275, 2011.
- Q. Yang, P. B. Smith, R. N. Goldberg, and C. M. Cotten, “Dynamic change of fecal calprotectin in very low birth weight infants during the first month of life,” Neonatology, vol. 94, no. 4, pp. 267–271, 2008.
- D. Carroll, A. Corfield, R. Spicer, and P. Cairns, “Faecal calprotectin concentrations and diagnosis of necrotising enterocolitis,” The Lancet, vol. 361, no. 9354, pp. 310–311, 2003.
- G. Aydemir, F. Kekmez, I. A. Yanju, et al., “Increased fecal calprotecitn in preterm infants with necrotizing enterocolitis,” Clinical Laboratory, vol. 58, pp. 841–844, 2012.
- K. W. Reisinger, D. C. van der Zee, H. A. Brouwers, et al., “Non-invasive measurement of calprotectin and serum amyloid a combined with intestinal fatty acid-binding protein in necrotizing enterocolitis,” Journal of Pediatric Surgery, vol. 47, no. 9, pp. 1640–1645, 2012.
- M. A. Selimoglu, I. Temel, Ç. Yildirim, F. Özyalin, M. Aktaş, and H. Karabiber, “The role of fecal calprotectin and lactoferrin in the diagnosis of necrotizing enterocolitis,” Pediatric Critical Care Medicine, vol. 13, no. 4, pp. 452–454, 2011.
- N. Balamtekin, M. Demir, G. Baysoy, et al., “Fecal calprotectin concentration is increased in children with celiac diseases: relation with histopathological findings,” Turkish Journal of Gastroenterology, vol. 23, no. 5, pp. 503–508, 2012.
- V. Ertekin, M. A. Selimoglu, A. Turgut, and N. Bakan, “Fecal calprotectin concentration in celiac disease,” Journal of Clinical Gastroenterology, vol. 44, no. 8, pp. 544–546, 2010.
- E. Bruzzese, V. Raia, G. Gaudiello et al., “Intestinal inflammation is a frequent feature of cystic fibrosis and is reduced by probiotic administration,” Alimentary Pharmacology and Therapeutics, vol. 20, no. 7, pp. 813–819, 2004.
- J. M. Lee, S. T. Leach, T. Katz, A. S. Day, A. Jaffe, and C. Y. Ooi, “Update of faecal markers of inflammation in children with cystic fibrosis,” Mediators of Inflammation, vol. 2012, Article ID 948367, 6 pages, 2012.
- E. Hestvik, E. Ollafstottir, T. Tylleskar, et al., “Fecal calprotectin in HIV-infected, HAAR-naïve Ugandan children,” Journal of Pediatric Gastroenterology and Nutrition, vol. 54, no. 6, pp. 785–790, 2012.
- G. Terrin, A. Passariello, M. D. Curtis, R. Paludetto, and R. B. Canani, “S100A8/A9 protein is a marker for early diagnosis of necrotizing enterocolitis in neonates,” Archives of Disease in Childhood, vol. 97, no. 12, p. 1102, 2012.
- M. Frosch, M. Ahlmann, T. Vogl et al., “The myeloid-related proteins 8 and 14 complex, a novel ligand of toll-like receptor 4, and interleukin-1β form a positive feedback mechanism in systemic-onset juvenile idiopathic arthritis,” Arthritis and Rheumatism, vol. 60, no. 3, pp. 883–891, 2009.
- A. Schulze zur Wiesch, D. Foell, M. Frosch, T. Vogl, C. Sorg, and J. Roth, “Myeloid related proteins MRP8/MRP14 may predict disease flares in juvenile idiopathic arthritis,” Clinical and Experimental Rheumatology, vol. 22, no. 3, pp. 368–373, 2004.
- J. Gerss, J. Roth, D. Holzinger, et al., “Phagocyte-specific S100 proteins and high-sensitivity C reactive protein as biomarkers for a nik-adapted treatment to maintain remission in juvenile idiopathic arthritis: a comparative study,” Annals of the Rheumatic Diseases, vol. 71, no. 12, pp. 1991–1997, 2012.
- D. Foell, M. Frosch, A. Schulze zur Wiesch, T. Vogl, C. Sorg, and J. Roth, “Methotrexate treatment in juvenile idiopathic arthritis: when is the right time to stop?” Annals of the Rheumatic Diseases, vol. 63, no. 2, pp. 206–208, 2004.
- M. Frosch, D. Metze, D. Foell et al., “Early activation of cutaneous vessels and epithelial cells is characteristic of acute systemic onset juvenile idiopathic arthritis,” Experimental Dermatology, vol. 14, no. 4, pp. 259–265, 2005.
- N. M. Wulffraat, P. J. Haas, M. Frosch et al., “Myeloid related protein 8 and 14 secretion reflects phagocyte activation and correlates with disease activity in juvenile idiopathic arthritis treated with autologous stem cell transplantation,” Annals of the Rheumatic Diseases, vol. 62, no. 3, pp. 236–241, 2003.
- K. Hirono, D. Foell, Y. Xing et al., “Expression of Myeloid-Related Protein-8 and -14 in Patients With Acute Kawasaki Disease,” Journal of the American College of Cardiology, vol. 48, no. 6, pp. 1257–1264, 2006.
- J. Abe, T. Jibiki, S. Noma, T. Nakajima, H. Saito, and M. Terai, “Gene expression profiling of the effect of high-dose intravenous Ig in patients with Kawasaki disease,” Journal of Immunology, vol. 174, no. 9, pp. 5837–5845, 2005.
- G. Guggino, R. Cimaz, S. Accamndo, et al., “Increased percentages of tumor necrosis factor-alpha+/interferon-gamma +T[corrected] lymphocytes and calprotectin+/tumor necrosis factor-alpha+monocytes in patients with acute Kawasaki disease,” International Journal of Immunopathology and Pharmacology, vol. 25, no. 1, pp. 99–105, 2012.
- T. Aoki, Y. Matsumoto, K. Hirata et al., “Expression profiling of genes related to asthma exacerbations,” Clinical and Experimental Allergy, vol. 39, no. 2, pp. 213–221, 2009.
- W. Renaud, M. Merten, and C. Figarella, “Increased coexpression of CFTR and S100 calcium binding proteins MRP8 and MRP14 mRNAs in cystic fibrosis human tracheal gland cells,” Biochemical and Biophysical Research Communications, vol. 201, no. 3, pp. 1518–1525, 1994.
- B. E. Golden, P. A. Clohessy, G. Russell, and M. K. Fagerhol, “Calprotectin as a marker of inflammation in cystic fibrosis,” Archives of Disease in Childhood, vol. 74, no. 2, pp. 136–139, 1996.
- R. K. Kumar, Z. Yang, S. Bilson, S. Thliveris, B. E. Cooke, and C. L. Geczy, “Dimeric S100A8 in human neutrophils is diminished after phagocytosis,” Journal of Leukocyte Biology, vol. 70, no. 1, pp. 59–64, 2001.
- J. F. Bealer and M. Colgin, “S100A8/A9: a potential new diagnostic aid for acute appendicitis,” Academic Emergency Medicine, vol. 17, no. 3, pp. 333–336, 2010.
- G. Thuijls, J. P. Derikx, F. J. Prakken et al., “A pilot study on potential new plasma markers for diagnosis of acute appendicitis,” American Journal of Emergency Medicine, vol. 29, no. 3, pp. 256–260, 2011.
- A. B. Kharbanda, A. J. Rai, Y. Cosme, K. Liu, and P. S. Dayan, “Novel serum and urine markers for pediatric appendicitis,” Academic Emergency Medicine, vol. 19, no. 1, pp. 56–62, 2012.
- “BET 3: super calprotectin will not expedite your discharge,” Emergency Medical Journal, vol. 30, no. 8, pp. 691–693, 2013.
- B. Sampson, M. K. Fagerhol, C. Sunderkötter et al., “Hyperzincaemia and hypercalprotectinaemia: a new disorder of zinc metabolism,” The Lancet, vol. 360, no. 9347, pp. 1742–1745, 2002.
- Y. Saito, K. Saito, Y. Hirano et al., “Hyperzincemia with systemic inflammation: a heritable disorder of calprotectin metabolism with rheumatic manifestations?” Journal of Pediatrics, vol. 140, no. 2, pp. 267–269, 2002.
- S. Fessatou, M. K. Fagerhol, J. Roth et al., “Severe anemia and neutropenia associated with hyperzincemia and hypercalprotectinemia,” Journal of Pediatric Hematology/Oncology, vol. 27, no. 9, pp. 477–480, 2005.
- T. Sugiura, K. Goto, K. Ito et al., “Effects of cyclosporine A in hyperzincaemia and hypercalprotectinaemia,” Acta Paediatrica, vol. 95, no. 7, pp. 857–860, 2006.
- B. Isidor, S. Poignant, N. Corradini et al., “Hyperzincemia and hypercalprotectinemia: unsuccessful treatment with tacrolimus,” Acta Paediatrica, vol. 98, no. 2, pp. 410–412, 2009.
- G. Lionetti, J. A. Bernstein, D. Holzinger, et al., “IL-1 blockade as a novel approach to treatment of hyperzicemia and hypercalprotectinemia, a possible new autoinflammatory syndrome,” Pediatric Rheumatology, vol. 10, supplement 1, article A87, 2012.
- G. Bordmann, G. Burmeister, S. Saladin et al., “MRP 8/14 as marker for Plasmodium falciparum-induced malaria episodes in individuals in a holoendemic area,” Clinical and Diagnostic Laboratory Immunology, vol. 4, no. 4, pp. 435–439, 1997.
- M. Frosch, T. Vogl, R. Waldherr, C. Sorg, C. Sunderkötter, and J. Roth, “Expression of MRP8 and MRP14 by macrophages is a marker for severe forms of glomerulonephritis,” Journal of Leukocyte Biology, vol. 75, no. 2, pp. 198–206, 2004.
- Y. Kawasaki, M. Hosoya, A. Takahashi, M. Isome, M. Tanji, and H. Suzuki, “Myeloid-related protein 8 expression on macrophages is a useful prognostic marker for renal dysfunction in children with MPGN type 1,” American Journal of Kidney Diseases, vol. 45, no. 3, pp. 510–518, 2005.
- Y. Kawasaki, K. Suyama, H. Go et al., “Accumulation of macrophages expressing myeloid-related protein 8 associated with the progression of sclerotic changes in children with IgA nephropathy,” Tohoku Journal of Experimental Medicine, vol. 218, no. 1, pp. 49–55, 2009.
- K. M. Rostasy, M. Piepkorn, H.-H. Goebel, S. Menck, F. Hanefeld, and W. J. Schulz-Schaeffer, “Monocyte/macrophage differentiation in dermatomyositis and polymyositis,” Muscle and Nerve, vol. 30, no. 2, pp. 225–230, 2004.
- J. M. Ehrchen, C. Sunderkötter, D. Foell, T. Vogl, and J. Roth, “The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer,” Journal of Leukocyte Biology, vol. 86, no. 3, pp. 557–566, 2009.
- C. Gebhardt, J. Németh, P. Angel, and J. Hess, “S100A8 and S100A9 in inflammation and cancer,” Biochemical Pharmacology, vol. 72, no. 11, pp. 1622–1631, 2006.
- F. Morandi, P. Scaruffi, F. Gallo et al., “Bone marrow-infiltrating human neuroblastoma cells express high levels of calprotectin and HLA-g proteins,” PLoS ONE, vol. 7, no. 1, Article ID e29922, 2012.